Company news

Veracyte, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

New Data at ASCO GU Show Power of Veracyte’s Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and Bladder Cancer Research

February 13, 2025

Veracyte Announces 17 Abstracts Demonstrating Its Decipher Tests’ Leadership in Urologic Cancers to Be Presented at the 2025 ASCO GU Symposium

February 10, 2025

New Study Shows Veracyte’s Decipher Bladder Test Predicts Disease Upstaging in Patients with Bladder Cancer

February 4, 2025

Veracyte to Release Fourth Quarter and Full-Year 2024 Financial Results on February 24, 2025

February 3, 2025

Veracyte’s Decipher Prostate Test Is Now the Only Gene Expression Test Recommended in NCCN® Prostate Cancer Guidelines

December 4, 2024

Veracyte Announces Third Quarter 2024 Financial Results

November 5, 2024

Veracyte to Release Third Quarter 2024 Financial Results on November 6, 2024

October 15, 2024

New Data Presented at ASTRO 2024 Show that Veracyte’s Decipher Prostate Test Predicts Aggressive Prostate Cancer in African American Men

October 1, 2024

New Data Presented at ESMO 2024 Show that Veracyte’s Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer

September 14, 2024

Veracyte Appoints Brent Shafer and Tom Miller, Ph.D., to Its Board of Directors

September 3, 2024

Veracyte to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

August 25, 2024

Veracyte Named a Greater Bay Area Top Workplace by the San Francisco Chronicle

August 25, 2024

Veracyte Announces Second Quarter 2024 Financial Results

August 5, 2024

Veracyte to Release Second Quarter 2024 Financial Results on August 6, 2024

July 16, 2024

Veracyte Announces that New Afirma GRID Data Suggest Prognostic Ability of Molecular Testing for Thyroid Tumors

June 2, 2024

Veracyte Announces Multiple Afirma GRID Presentations at ENDO 2024, Previewing the Future of Molecular Testing in Thyroid Nodules and Cancer

May 21, 2024

Veracyte Announces First Quarter 2024 Financial Results

May 6, 2024

14 Studies Presented at AUA 2024 Show Decipher Tests’ Ability to Help Personalize Care for Prostate and Bladder Cancer Patients and Advance Disease Understanding

May 5, 2024

Veracyte to Release First Quarter 2024 Financial Results on May 7, 2024

April 21, 2024

New Study Shows Veracyte’s Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance

April 21, 2024

Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024

April 15, 2024

Veracyte’s Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines

February 26, 2024

Veracyte Announces Fourth Quarter and Full-Year 2023 Financial Results

February 21, 2024

Veracyte to Participate in the Raymond James 45th Annual Institutional Investors Conference

February 20, 2024

Veracyte to Release Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024

February 7, 2024

Veracyte Completes Acquisition of C2i Genomics

February 5, 2024

Veracyte Announces Preliminary Full-Year 2023 Results, Acquisition of C2i Genomics to Add Minimal Residual Disease Capabilities to Its Novel Diagnostics Platform

January 7, 2024

Veracyte to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

December 11, 2023

Real-World Data Presented at SUO 2023 Show that Veracyte’s Decipher Genomic Classifier Identifies Patients Whose Prostate Cancer is Likely to Progress

November 30, 2023

Clinical Validation Data Published in CHEST Demonstrate that Veracyte’s Percepta Nasal Swab Test Improves Lung Cancer Risk Assessment for Patients with Lung Nodules

November 28, 2023

Veracyte Announces Seven Posters Highlighting Clinical Value of Decipher Prostate Genomic Testing To be Presented at SUO 2023

November 21, 2023

Veracyte Announces Third Quarter 2023 Financial Results

November 6, 2023

Veracyte Announces In Vitro Diagnostic Agreement with Illumina to Broaden Availability of Its Tests for Patients Globally

November 6, 2023

Veracyte to Participate in the Stephens Annual Investment Conference

November 1, 2023

Veracyte Announces SITC 2023 Presentations Offering New Insight into Immuno-oncology Drug Development

October 26, 2023

Veracyte to Release Third Quarter 2023 Financial Results on November 7, 2023

October 16, 2023

New Data Presented at CHEST 2023 Demonstrate the Clinical Utility of Veracyte’s Envisia Genomic Classifier for Patients with Interstitial Lung Disease

October 11, 2023

New Data from Phase 3 Trial Further Validate Prognostic Value of Veracyte’s Decipher Prostate Genomic Classifier

October 3, 2023

Veracyte Announces Multiple Studies Reinforcing the Value of Decipher Prostate Testing Will Be Presented at ASTRO 2023

September 27, 2023

New Data Presented at the 2023 ATA Annual Meeting Demonstrate that Veracyte’s Afirma-Based Testing Can Uncover Key Molecular Hallmarks of Thyroid Cancer

September 27, 2023

Veracyte Names Phillip G. Febbo, M.D., as Chief Scientific Officer and Chief Medical Officer

September 26, 2023

Veracyte Announces Novel Afirma-Based Findings that Advance Molecular Understanding of Thyroid Cancer to Be Presented at the 2023 ATA Annual Meeting

September 20, 2023

Veracyte Names Marie-Claire Taine, Ph.D., as General Manager of Its IVD Business Unit To Advance Global Expansion of the Company’s Tests

September 6, 2023

Veracyte and Gustave Roussy Announce Collaboration to Help Biopharmaceutical Companies Accelerate Development of Novel Cancer Therapies

September 5, 2023

Veracyte to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

August 28, 2023

Veracyte Announces that Findings Published in JCO Precision Oncology Suggest Potential of Decipher GRID-Derived Gene Signatures to Predict Treatment Response in Recurrent Prostate Cancer

August 21, 2023

Veracyte Earns Top Workplace Awards in the San Francisco Bay Area and San Diego

August 14, 2023

Veracyte Announces Second Quarter 2023 Financial Results

August 7, 2023

Study Published in JNCI Cancer Spectrum Demonstrates Real-World Utility of Veracyte’s Decipher Prostate Genomic Classifier in Prostate Cancer Treatment

July 31, 2023

Veracyte to Release Second Quarter 2023 Financial Results on August 8, 2023

July 18, 2023

← Newer news releases · Older news releases →

Calls

The 5 newest of 24 calls. Every call is listed under its year.

Decks

The 5 newest of 19 decks. Every deck is listed under its year.